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AbstrACt
Introduction In women with gestational diabetes mellitus 
(GDM) requiring pharmacotherapy, insulin was the established 
first-line treatment. More recently, oral glucose lowering 
drugs (OGLDs) have gained popularity as a patient-friendly, 
less expensive and safe alternative. Monotherapy with 
metformin or glibenclamide (glyburide) is incorporated in 
several international guidelines. In women who do not reach 
sufficient glucose control with OGLD monotherapy, usually 
insulin is added, either with or without continuation of OGLDs. 
No reliable data from clinical trials, however, are available 
on the effectiveness of a treatment strategy using all three 
agents, metformin, glibenclamide and insulin, in a stepwise 
approach, compared with insulin-only therapy for improving 
pregnancy outcomes. In this trial, we aim to assess the clinical 
effectiveness, cost-effectiveness and patient experience of a 
stepwise combined OGLD treatment protocol, compared with 
conventional insulin-based therapy for GDM.
Methods The SUGAR-DIP trial is an open-label, 
multicentre randomised controlled non-inferiority trial. 
Participants are women with GDM who do not reach target 
glycaemic control with modification of diet, between 16 
and 34 weeks of gestation. Participants will be randomised 
to either treatment with OGLDs, starting with metformin 
and supplemented as needed with glibenclamide, or 
randomised to treatment with insulin. In women who 
do not reach target glycaemic control with combined 
metformin and glibenclamide, glibenclamide will be 
substituted with insulin, while continuing metformin. 
The primary outcome will be the incidence of large-for-
gestational-age infants (birth weight >90th percentile). 
Secondary outcome measures are maternal diabetes-
related endpoints, obstetric complications, neonatal 
complications and cost-effectiveness analysis. Outcomes 
will be analysed according to the intention-to-treat 
principle.
Ethics and dissemination The study protocol was 
approved by the Ethics Committee of the Utrecht University 
Medical Centre. Approval by the boards of management for 
all participating hospitals will be obtained. Trial results will 
be submitted for publication in peer-reviewed journals.
trial registration number NTR6134; Pre-results.
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IntroduCtIon
The prevalence of gestational diabetes mellitus (GDM) 
is rising and currently affects approximately 1%–28% 
of all pregnancies, varying by region and diagnostic 
criteria used.1–4 GDM carries significant perinatal risks 
for pregnancy and childbirth, such as polyhydram-
nios, small-for-gestational-age and large-for-gestation-
al-age infants, macrosomia, stillbirth, shoulder dystocia, 
obstructed labour, pre-eclampsia (PE) and neonatal 
hypoglycaemia.5–9 In addition, increasing concern exists 
about the impact of GDM on offspring development and 
associated long-term risks for glucose and insulin resis-
tance, obesity and chronic disease in children born to 
mothers with GDM.10–12 
The rising number of women diagnosed with GDM is 
increasingly putting pressure on healthcare resources. 
Effective treatment for GDM treatment requires a multi-
disciplinary approach by midwives, obstetricians, dieti-
cians, endocrinologists and diabetes nurse specialists. 
Current treatment of GDM focuses on achieving optimal 
glycaemic control. When blood glucose levels, usually 
based on self-monitoring, fall outside the target range 
despite lifestyle and dietary advice, treatment with anti-
hyperglycaemic medication is indicated.13 14 As phar-
macological treatment, subcutaneous insulin injections 
have traditionally been used as first-choice treatment for 
GDM and is still advocated in many,15–18 but not all guide-
lines.19–21 In recent years, clinical research and expe-
rience with oral glucose lowering drugs (OGLDs) has 
shown promising results as a treatment alternative that 
may substitute insulin in many women.22 23
Metformin and glibenclamide (glyburide) are the 
OGLDs most studied for diabetes in pregnancy. Both are 
already widely used in the treatment of GDM, considered 
to be safe and have been incorporated in several guide-
lines as treatment options alongside insulin.19–21 24 25 A 
2014 retrospective cohort study from the USA showed 
that the use of glibenclamide had increased from 7.4% in 
2000 to 64.5% in 2011, becoming the most common treat-
ment for GDM requiring pharmacotherapy in 2007.26 In 
the UK, incorporated in NICE guidelines (National Insti-
tute for Health and Care Excellence, UK), metformin 
is the first-choice treatment, supplemented with insulin 
if needed.19 Insulin is offered to women if metformin is 
contraindicated or unacceptable to the patient, or target 
glucose values are not met with metformin only. NICE 
guidelines state that glibenclamide could be considered 
an option for women in whom blood glucose targets are 
not achieved with metformin, but decline insulin therapy, 
or for those who cannot tolerate metformin. The Inter-
national Federation of Gynaecology and Obstetrics and 
more recently the Society of Maternal-Fetal Medicine 
Committee further endorsed OGLDs as a reasonable and 
safe first-line pharmacological treatment option in GDM, 
with metformin being preferred over glibenclamide.21 25 
In contrast, in the Netherlands, insulin has remained the 
drug of choice in the majority of hospitals.
Two 2017 Cochrane Reviews on 11 and 53 studies 
(1487 and 7381 women) concluded that due to insuffi-
cient high-quality evidence, no single agent is superior 
in the treatment of GDM.27 28 And although the use of 
OGLDs is widespread, there is an ongoing discussion on 
which drug should be first-line treatment after lifestyle 
and dietary interventions.24 Both insulin and oral agents 
have advantages and disadvantages. Insulin is safe and 
effective; however, it is considered burdensome by preg-
nant women, requires intensive glucose monitoring and 
is associated with episodes of maternal hypoglycaemia.29 
OGLDs are less costly, less burdensome and associated 
with higher patient satisfaction.23 30–33 Metformin has 
the advantage over insulin that hypoglycaemic events 
do not occur, but it is less potent when compared with 
glibenclamide, can cause gastrointestinal side effects and 
is possibly associated with more spontaneous preterm 
deliveries.34 Glibenclamide, similar to insulin, is more 
potent in its glucose-lowering effect and may cause hypo-
glycaemia in the mother and newborn.22 35 Other unde-
sirable effects include gastrointestinal reactions, allergic 
skin reactions, altered liver enzyme values, visual distur-
bances and weight gain. And although intrauterine expo-
sure to metformin or glibenclamide is not associated with 
congenital anomalies, much less is known about direct 
fetal metabolic effects and long-term effects on mothers 
and offspring.36
With current OGLD monotherapy, consisting of 
either metformin or glibenclamide, in women who do 
not reach glycaemic control, prompting the need for 
additional measures, in general OGLDs are replaced by 
or supplemented with insulin. A combination of oral 
agents may be an interesting strategy for GDM treat-
ment; however, current evidence is insufficient to deter-
mine the optimal use of OGLDs. In a recent randomised 
controlled trial (RCT) by Nachum et al in 104 women 
with GDM, powered for glycaemic control, combination 
therapy of metformin and glibenclamide decreased the 
need for additional insulin from 32% to 11% (p=0.0002) 
compared with monotherapy.37 Metformin as the first-
line therapy combined with glibenclamide if needed was 
associated with the highest treatment success. These data 
support the need for a well-powered large-scale RCT to 
compare a stepwise approach combining metformin and 
strengths and limitations of this study
 ► This is the first open-label randomised controlled trial that directly 
compares a stepwise treatment protocol using a combination of oral 
glucose lowering drugs (OGLDs) with insulin as a first-line treatment 
for gestational diabetes mellitus  (GDM) not responding to diet.
 ► The randomised multicentre design minimises the risk of bias and 
increases generalisability of the results.
 ► Variation in diagnostic thresholds and treatment targets for GDM 
may need to be addressed to assess the value of this strategy 
across different populations.
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glibenclamide to conventional insulin therapy to study 
effects on pregnancy outcomes.
In the SUGAR-DIP trial, a multicentre RCT, we aim to 
assess non-inferiority of treatment with metformin, and 
in case of insufficient glycaemic control the addition 
of glibenclamide, compared with immediate insulin in 
the treatment of GDM. We expect that a proportion of 
patients will achieve glycaemic control with metformin 
only. By adding glibenclamide in combined treatment 
with metformin, we expect to achieve glycaemic control 
as good as by insulin, while maintaining the benefits and 
ease of a less burdensome treatment with oral medication. 
We will assess the clinical effectiveness, cost-effectiveness 
and patient experience of stepwise oral antihypergly-
caemic medication to treat GDM compared with conven-
tional insulin-based treatment strategy.
MEthods
design and setting
The SUGAR-DIP trial is a multicentre non-inferiority 
RCT. The study will be open label as oral drugs and insulin 
cannot be administered individually in a blinded way. The 
study will be conducted within the setting of the Dutch 
Consortium for Healthcare Evaluation and Research in 
Obstetrics and Gynaecology—NVOG Consortium 2.0,38 a 
collaborative network of all major hospitals in the Neth-
erlands and the Dutch Society of Obstetrics and Gynae-
cology (NVOG) and performed by treatment teams 
generally consisting of an internal medicine specialist, a 
gynaecologist and diabetes nurses. The trial was approved 
by the Medical Research Ethics Committee (MREC) of 
the UMC Utrecht. Trial reference number: 16–523/M. 
The trial is registered in the Netherlands Trial Registry 
on 29 November 2016 under the number NTR6134.39
Patient and public involvement
In the preparation of the trial, the patient organisation 
Dutch Diabetes Association (Diabetes Vereniging Neder-
land) was involved. A questionnaire on patient perspec-
tives of women who have (had) GDM was issued by 
the organisation prior to the development of the study 
protocol. The organisation was furthermore involved in 
reviewing the study protocol and provided valuable input 
in the development of the information material used in 
the study. On completion of the trial, the patient organisa-
tion will be involved in dissemination of the study results.
Participants and eligibility criteria
Women diagnosed with GDM who have not reached 
target glycaemic control with dietary and lifestyle adapta-
tions and thus meet the criteria for additional treatment 
with antihyperglycaemic medication between 16 and 34 
weeks of gestation will be eligible for inclusion. Target 
glycaemic control is defined by the NVOG (Dutch Society 
O&G) diabetes in pregnancy guideline as a fasting 
glucose concentration <5.3 mmol/L, 1-hour postpran-
dial <7.8 mmol/L or 2-hour postprandial <6.7 mmol/L.18
The diagnosis of GDM is made according to Dutch 
national guidelines, using a 75-gram oral glucose toler-
ance test (OGTT).18 Due to a transition in diagnostic 
thresholds, both the WHO 1999 (fasting >7.0 mmol/L 
or 2-hour postload >7.8 mmol/L) and the WHO 2013 
criteria (fasting >5.1 mmol/L, 1-hour postload >10.0 or 
2-hour postload >8.5 mmol/L) for venous plasma glucose 
values were used to diagnose GDM. The 100-gram OGTT 
is incorporated in the study protocol, as it is part of 
the Dutch national guideline; however, this test is not 
commonly used in the Netherlands. Although thresh-
olds for the diagnosis of GDM in the Netherlands and 
therefore in the trial are divergent to some extent, the 
target glucose values to define insufficient glycaemic 
control (while on diet) as the additional inclusion crite-
rion for enrolment in the trial apply to all centres. It is 
thus expected that patients eligible for enrolment form 
a homogeneous group despite differences in screening 
tools.
Screening in the Netherlands is conducted according to 
a high risk strategy and takes place in the second trimester 
(24–28 weeks) among pregnant women with one or more 
of the following risk factors: a history of GDM, body 
mass index (BMI) >30 (kg/m2), a history of a neonate 
with a birth weight >95th percentile or >4500 grams, a 
first degree family member with diabetes, polycystic ovary 
syndrome, a history of an unexplained intrauterine death 
or an ethnicity with higher diabetes risk (eg, women from 
South Asia, Indian descent/Surinamese, Afro-Carib-
bean, Middle-Eastern, Moroccan or Egyptian ethnicity). 
In case of a history of GDM in a previous pregnancy, an 
OGTT as early as 16 weeks of gestation is recommended, 
to be repeated at 24–28 weeks if normal. An OGTT may 
furthermore be performed in case of suspected fetal 
macrosomia, polyhydramnios or symptoms of polydipsia 
or polyuria, also in women without risk factors.
For the SUGAR-DIP trial, we have set the upper limit 
for inclusion to 34 weeks, in line with previous trials,22 23 40 
allowing at least 4 weeks of exposure to pharmacological 
treatment. With the timing of the OGTT in current guide-
lines, it is expected that the majority of women will be 
treated for over 8 weeks. Although in women diagnosed 
later in pregnancy exposure to treatment may have less 
of an effect on the primary outcome, treatment may still 
influence several important secondary outcomes, such as 
neonatal hypoglycaemia.
Additional inclusion criteria for the SUGAR-DIP trial are 
(1) maternal age >18 years, (2) singleton pregnancy, (3) 
ability to understand the Dutch or English language and 
(4) ability to provide written informed consent. Patients 
who meet any of the following criteria are excluded from 
the study: (1) known pre-existing type 1 or type 2 diabetes 
mellitus, (2) severe medical or psychiatric comorbidities, 
(3) significant liver disease or renal insufficiency, or any 
other known condition with contraindications for the use 
of either metformin or glibenclamide and (4) pregnancy 
with a fetus affected by major congenital birth defects 
and/or chromosomal abnormality.
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recruitment and randomisation
Eligible women will be informed and invited to participate 
by either their diabetes care or obstetric care provider, 
that is, physician, obstetrician, midwife or diabetes 
nurse. Following counselling, written informed consent 
is obtained and participants are individually randomised 
to either stepwise OGLDs or insulin. Randomisation is 
performed through a central web-based tool (Castor 
EDC, Ciwit B.V., Amsterdam, the Netherlands) using a 
1:1 ratio and block randomisation with a variable block 
size of 4 and 6.
Intervention and control
The stepwise treatment strategy for the intervention 
(OLGD) and control (insulin) group is displayed in 
figure 1.
Figure 1 Flowchart of comparator (oral glucose lowering drugs) versus control (insulin). GDM, gestational diabetes mellitus.
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Oral glucose lowering drugs
In women allocated to the OGLD strategy, metformin is 
initiated with a starting dose of 500 mg once daily for 3 
days, followed by an increase of 500 mg every 3 days to 
the final daily dose of 2000 mg divided into two doses. In 
case of serious side effects (eg, severe nausea, persistent 
vomiting or diarrhoea), the metformin dose can be 
lowered to the maximum dose tolerated with acceptable 
side effects. Participants are advised to take metformin 
during or shortly after a meal to reduce side effects. In 
case of insufficient glycaemic control with metformin at 
the maximum (tolerated) dose, glibenclamide will be 
added at a starting dose of 2.5 mg once daily. Gliben-
clamide can be increased if glycaemic goals are not met 
with increments of 2.5 mg every week, up to a maximum 
dose of 15 mg daily. In case of insufficient glycaemic 
control with both metformin and glibenclamide at the 
maximum doses, glibenclamide will be discontinued and 
replaced by insulin, while metformin will be continued.
Insulin
Participants randomised to insulin treatment will receive 
insulin according to usual practice, that is, in incremental 
doses until glycaemic targets are met.41 This includes 
both short-acting and long-acting insulin.
study procedures
Diabetes care
In all participants, a specialised diabetes nurse or 
internal medicine specialist will review glycaemic control 
every 1–2 weeks using the following target values for 
glucose, as measured by capillary glucose self-testing: 
fasting <5.3 mmol/L, 1-hour postprandial <7.8 mmol/L 
and 2-hours postprandial <6.7 mmol/L. If titration of 
medication requires more frequent feedback, partici-
pants will be given the option to contact their diabetes 
treatment specialist in between scheduled visits. All partic-
ipants receive the usual instructions regarding hypogly-
caemic events (glucose <4.0 mmol/L). A participant diary 
is used to document glucose values and medication use, 
and is reviewed at every visit. Frequency of self-monitoring 
will be discussed on an individual basis with the treating 
diabetes team. Weight is documented at study inclusion 
and at every subsequent visit. Blood sampling for glycated 
haemoglobin (HbA1c) is performed at study inclusion, at 
30 weeks and at 36 weeks of pregnancy.
Obstetric care
All participants will receive obstetrical care based on usual 
practice for GDM requiring pharmacological therapy. 
This includes assessment of fetal biometry at weeks 
26–28, 30–32 and 34–36 of pregnancy by measuring fetal 
abdominal circumference, femur length, head circum-
ference, estimated fetal weight (Hadlock or similar) and 
amniotic fluid volume. The timing of delivery follows 
local protocol, based on national guidelines.18 Induc-
tion of labour around 38–39 weeks of gestation is gener-
ally recommended for women with GDM requiring 
medication. Both oral antihyperglycaemic agents and 
insulin may be discontinued on the day of delivery in case 
of induced labour or as soon as labour is established after 
spontaneous onset. Monitoring of glucose levels during 
labour is advised.
Neonatal care
Neonatal glucose monitoring will be performed serially 
for up to 12–24 hours after delivery in accordance to local 
protocol in participating sites. We defined neonatal hypo-
glycaemia as a plasma glucose concentration <2.6 mmol/L 
and severe neonatal hypoglycaemia as <2.0 mmol/L.42 
Time and plasma glucose values are documented, as 
well interventions used, to regulate neonatal glucoses. 
Furthermore, any admission to a neonatal medium care 
or intensive care unit is documented.
Postpartum
Participants will attend routine obstetric and diabetes care 
provider appointments around 5–6 weeks postpartum at 
which time glucose self-monitoring will be carried out to 
detect persistent postpartum hyperglycaemia.
outcome measures
Primary outcome measure
The primary outcome is a large-for-gestational-age (LGA) 
infant. LGA is defined as a birth weight >90th percentile 
using the Dutch Perinatal Registry reference charts.43
Secondary outcome measures
Secondary outcomes include maternal hypoglycaemia 
(biochemical hypoglycaemia <3.9 mmol/L, symptomatic 
hypoglycaemia, severe hypoglycaemia prompting the need 
for help by another person and/or hospital admission for 
hypoglycaemia), elective and emergency caesarean section, 
pregnancy-related hypertensive disorders including preg-
nancy-induced hypertension and PE, preterm delivery 
(delivery <37 weeks of gestation), postpartum neonatal 
hypoglycaemia (moderate: serum glucose <2.6 mmol/L, 
severe: serum glucose <2.0 mmol/L), neonatal hyperbil-
irubinaemia requiring phototherapy, neonatal medium 
care or intensive care admission and a cost-effectiveness 
analysis. These secondary outcomes were selected based 
on their clinical relevance and/or observed differences in 
previous studies comparing OGLDs and insulin.
Furthermore, a number of maternal baseline charac-
teristics, additional obstetric- and neonatal outcomes, 
diabetes-related endpoints, biomarkers and laboratory 
examinations will be assessed (see online supplementary 
file 1 and 2).
Follow-up
Details regarding outcomes, including maternal and 
neonatal hospital admissions or complications, are 
recorded up to 6 weeks postpartum. Long-term follow-up 
of mother and child is not part of the initial trial; however, 
participants will be informed about planned long-term 
follow-up and asked to provide additional personal 
Protected by copyright.
 o
n
 N
ovem
ber 4, 2019 at Radboud University Nijmegen.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029808 on 18 August 2019. Downloaded from 
6 de Wit L, et al. BMJ Open 2019;9:e029808. doi:10.1136/bmjopen-2019-029808
Open access 
information and contact details on the patient informa-
tion and informed consent form at study inclusion.
Patient perspective and treatment satisfaction
Side effects will be monitored using a custom-made form 
consisting of a short list of the most common side effects 
and the possibility to self-report any other experienced 
undesirable effects. The form will also address the actions 
taken as a response to side effects. Both treatment arms 
receive the same side effect form. Furthermore, treatment 
satisfaction is measured around 36 weeks of pregnancy 
using the Diabetes Treatment Satisfaction Question-
naire (DTSQ), consisting of eight questions regarding 
diabetes treatment and patient experience.44 45 Two addi-
tional questions regarding the impact of side effects and 
discomfort were provided by the copyright holder from a 
related treatment satisfaction measure for another condi-
tion, and added as items 9 and 10 of the DTSQ, to be 
analysed separately.46
safety and monitoring
An independent Data and Safety Monitoring Board will 
be established to safeguard the interests of trial partici-
pants, assess the safety and efficacy of the interventions 
during the trial period and monitor the overall conduct 
of the clinical trial. An interim safety review is planned at 
300 included participants and will be carried out by an 
independent statistician.
All serious adverse events (SAEs) reported by the 
subject or observed by the investigator or staff will be 
recorded. SAE definitions and standards for expedited 
reporting follow the International Council for Harmon-
isation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Good Clinical 
Practice (GCP) guidelines on safety reporting.47 All SAEs 
will be reported to the accredited ethics committee that 
approved the protocol, according to the requirements of 
that committee.
sample size
The primary outcome measure, rate of LGA infants, 
is anticipated to occur in 20% of patients in both study 
groups, based on a Dutch study cohort.48 We have set 
the non-inferiority limit at 8%, which is equivalent to 
excluding a relative risk in the OGLD treatment compared 
with conventional insulin-based therapy greater than 1.4. 
With a one-sided significance level (α) of 0.025 and a 
power of 0.8, the sample size is calculated at 393 patients 
in each arm. Accounting for a loss to follow-up of 3%, 810 
patients are needed (405 per arm).
Analyses and reporting of results
Primary and secondary outcomes
Primary analysis of the RCT results will be according to the 
intention-to-treat principle. Missing data will be handled 
according to the complete-case analysis principle, based 
on the availability of the components needed to deter-
mine the primary endpoint. Results will be reported 
according to Consolidated Standards of Reporting Trials 
guidelines, using the extension for non-inferiority trials. 
In case of substantial crossover (>5%), a per protocol anal-
ysis is used additionally to the intention-to-treat analysis. 
Crossover is defined as patients not receiving the treat-
ment allocated by randomisation (eg, participant never 
started treatment, treatment is no longer necessary for 
instance due to improved dietary adaptations, side effects 
or stopping treatment shortly after randomisation).
For the primary analysis, the non-inferiority of 
metformin/glibenclamide versus insulin for preventing 
LGA infants will be established when the upper bounds 
of the two-sided 95% CI for the risk ratio is less than 1.4. 
LGA will be defined as birth weight >90th percentile.43 
Results for the primary outcome will also be presented 
as absolute and relative risks (along with 95% CI) and 
numbers needed to treat (if applicable). Analyses will not 
be adjusted for any observed differences in baseline char-
acteristics between the arms.
The secondary outcome measures will be analysed 
similar to the primary outcome measure. Categorical 
secondary outcomes will be assessed by comparing the 
event rates in the two groups using a χ2 test with a p value 
of 0.05 and also by presenting absolute and relative risks. 
For continuous secondary outcomes, differences between 
groups will be assessed with the Student’s t-test if the 
outcome is normally distributed and with a non-para-
metric Mann-Whitney U test if skewed. These outcomes 
will be presented per group as means with SD, geometric 
means with 95% CI or as median with IQR, depending on 
distribution.
Subgroup analyses
Subgroup analyses will be performed for women 
with and without a history of GDM, a family history of 
diabetes mellitus (first and/or second degree relative), 
BMI (normal weight, overweight, obese), according 
to severity of GDM (fasting and 2-hour OGTT glucose 
value by various diagnostic criteria and cut-offs) and sex 
(neonate). Additionally, potential causes for treatment 
failure of metformin alone will also be explored. Within 
the patients receiving oral agents, the outcome rate will 
be compared between the patients whose blood glucose 
could be regulated by metformin alone and those patients 
who also required glibenclamide and even additional 
insulin. Patient characteristics between these groups will 
be compared to identify possible contributing factors to 
metformin treatment failure.
Economic evaluation
An economic evaluation will be conducted alongside 
the RCT according to guidelines issued by the National 
Healthcare Institute.49 The EuroQol questionnaire 
(EQ-5D-5L) for health status measures is used at time of 
study inclusion, 36 weeks of pregnancy and 4–6 weeks 
postpartum.50 Further Health Technology Assessment 
questionnaires are based on the iMTA PCQ (Productivity 
Cost Questionnaire) and MCQ (Medical Consumption 
Questionnaire), issued at 36 weeks of pregnancy and 
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4–6 weeks postpartum.51 52 The statistical analysis for 
the economic evaluation will be done according to the 
intention-to-treat principle. Missing data will be imputed 
using multiple imputation. If OGLDs are non-inferior to 
insulin as hypothesised, a cost minimisation analysis will 
be performed to investigate which intervention is associ-
ated with lower costs. If non-inferiority cannot be shown, 
a cost-effectiveness analysis will be performed. The costs 
will be analysed from both a societal (ie, healthcare costs, 
patient and family costs, and costs in other sectors) and 
healthcare perspective (ie, only healthcare costs). In 
the cost minimisation analysis, the differences in costs 
between OGLDs and insulin will be evaluated using linear 
multilevel regression models with adjustment for covari-
ates and effect modifiers if necessary. Bootstrapping with 
stratification for centre will be done to estimate 95% CI 
around differences in costs. In the cost-effectiveness anal-
ysis, cost and effect differences will be estimated using 
seemingly unrelated regression analyses while adjusting 
for confounders and effect modifiers if necessary. Incre-
mental cost-effectiveness ratios (ICERs) will be calculated 
by dividing the difference in mean total costs between 
the treatment groups by the difference in mean effects. 
Bootstrapping with stratification for centre will be used to 
estimate uncertainty surrounding the ICERs. Uncertainty 
surrounding the ICERs will be graphically presented on 
cost-effectiveness planes. Cost-effectiveness acceptability 
curves showing the probability that the intervention is 
cost-effective in comparison with usual care for a range 
of different ceiling ratios will also be estimated.53 A sensi-
tivity analysis will be performed to investigate the robust-
ness of the results to variation in the most influential cost 
parameters such as medication and time required for 
clinical consults.
data handling
Baseline data including patient demographics, obstetric 
and medical history, details regarding the pregnancy, 
delivery outcomes and diabetes treatment will be recorded 
using a web-based electronic case record form (eCRF) 
using Castor EDC. The eCRF is based on a standardised 
piloted eCRF that has been used in other multicentre 
trials within the NVOG Consortium 2.0 network and will 
be filled in by trained research nurses. The full eCRF is 
provided as online supplementary file 2. A study monitor 
will periodically visit participating centres, assessing 
quality of data and auditing trial conduct. Patient privacy 
will be ensured by allocation of unique participant 
numbers, which will be used on all study documentation. 
The participant code is only available to the local investi-
gator and research staff.
Ethics and dissemination
This trial has been approved by the Medical Research 
Ethics Committee (MREC) of the UMC Utrecht. Trial 
reference number: 16–523/G-M-X. The MREC of the 
UMC Utrecht is accredited by the Central Committee 
on Research Involving Human Subjects (CCMO) since 
November 1999. For all participating hospitals and 
study sites, approval by the boards of management will 
be obtained. The CCMO has issued a ‘No grounds for 
non-acceptance’ for the SUGAR-DIP trial. Research with 
a medicinal product must undergo an extra, marginal 
review alongside the review by the reviewing party 
(MREC). The competent authority (CCMO) checks if 
there are ‘motivated objections’ against the study. For 
this the European adverse reactions database (EudraVig-
ilance) is checked for any previously reported suspected 
adverse reactions to the medicinal product, which could 
lead to unacceptable risks to the participating research 
subject. Furthermore, the CCMO is responsible as the 
competent authority for entering data into the Euro-
pean EudraCT database. EudraCT number for this trial: 
2016-001401-16.
Changes to the study protocol are documented in 
amendments. Amendments are submitted for approval to 
the MREC. Major changes will be updated on the trial 
registration website.39 The full study protocol, including 
amendments, is publicly available on the study website.54
After completion of the trial, the principal investigator 
will report on the results of the main study and submit a 
manuscript to a peer-reviewed medical journal. Supple-
mentary analyses will be reported separately.
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